Amyloid Therapeutics: Investment Landscape Analysis

Overview

flowchart TD
    AMYLOID["AMYLOID"] -->|"associated with"| MICROGLIA["MICROGLIA"]
    AMYLOID["AMYLOID"] -->|"associated with"| TAU["TAU"]
    AMYLOID["AMYLOID"] -->|"associated with"| BACE1["BACE1"]
    AMYLOID["AMYLOID"] -->|"associated with"| AUTOPHAGY["AUTOPHAGY"]
    AMYLOID["AMYLOID"] -->|"associated with"| APOPTOSIS["APOPTOSIS"]
    AMYLOID["AMYLOID"] -->|"associated with"| GFAP["GFAP"]
    AMYLOID["AMYLOID"] -->|"associated with"| NEURON["NEURON"]
    AMYLOID["AMYLOID"] -->|"associated with"| SOD1["SOD1"]
    AMYLOID["AMYLOID"] -->|"associated with"| NLRP3["NLRP3"]
    AMYLOID["AMYLOID"] -->|"associated with"| SNCA["SNCA"]
    AMYLOID["AMYLOID"] -->|"associated with"| DEPRESSION["DEPRESSION"]
    AMYLOID["AMYLOID"] -->|"inhibits"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
    AMYLOID["AMYLOID"] -->|"activates"| GENES["GENES"]
    AMYLOID["AMYLOID"] -->|"inhibits"| Alzheimer["Alzheimer"]
    style amyloid fill:#4fc3f7,stroke:#333,color:#000

This page provides a comprehensive investment landscape analysis for amyloid-targeted therapeutics in Alzheimer’s disease and related neurodegenerative conditions. Amyloid-beta (Abeta) accumulation is a hallmark pathological feature of Alzheimer’s disease, and therapeutic approaches targeting amyloid represent the largest segment of the AD therapeutic pipeline. ^{1Citation2026}

This analysis is based on clinical trial data from the NeuroWiki Clinical Trials Index, last updated 2026-03-12.

Pipeline Metrics

Trial Status Distribution

Active vs Historical Summary

Phase Distribution

Mechanism Breakdown

Amyloid-targeted therapeutics can be categorized by their mechanism of action:

1. Anti-Aβ Monoclonal Antibodies

The largest mechanism category includes antibodies designed to bind and clear amyloid-beta plaques or soluble oligomers.

Key Programs:

• Leqembi (Lecanemab) - Eisai/Biogen - Anti-Aβ protofibril antibody, FDA approved

• Donanemab - Eli Lilly - Anti-Aβ plaque antibody, FDA approved

• Crenezumab - Roche/Genentech - Anti-Aβ oligomer antibody

• Gantenerumab - Roche - Anti-Aβ plaque antibody

• Solanezumab - Eli Lilly - Anti-Aβ soluble antibody

2. Aβ Aggregation Inhibitors

Small molecules designed to prevent the formation of or break down amyloid oligomers and plaques.

Key Programs:

• Contursi - Neurokine Therapeutics

• Curcumin derivatives - Multiple researchers

• NC-002 - New Century Therapeutics

3. BACE Inhibitors

Beta-secretase (BACE) inhibitors block the initial cleavage of APP to produce Aβ.

Note: Several BACE inhibitors have failed in late-stage trials due to safety concerns (verubecestat, atabecestat, CNP520).

4. Gamma Secretase Modulators

Modulators of the gamma secretase enzyme that shift Aβ production toward shorter, less aggregation-prone isoforms.

Key Programs:

• GSM-17 - Astellas Pharma

• E2012 - Eisai

5. Aβ Vaccines

Active immunization approaches to induce anti-Aβ antibody production.

Key Programs:

• ACI-35 - AC Immune/Li-Iyonga - Liposome-based tau vaccine

• ABvac40 - Araclon Biotech - Aβ40 vaccine

• CAD106 - Novartis/Cytos Biotechnology - Aβ immunotherapeutic

6. Aβ Degradation Enhancers

Approaches to enhance the clearance of Aβ through enzymatic degradation or cellular clearance mechanisms.

7. PET Imaging Agents

Diagnostic agents for amyloid plaque imaging:

• Pittsburgh Compound B (PiB) - Research use

• Florbetapir (Amyvid) - FDA approved for PET imaging

• Florbetaben (Neuraceq) - FDA approved for PET imaging

• Flutemetamol (Vizamyl) - FDA approved for PET imaging

Sponsor Landscape

Academic Medical Centers

Pharmaceutical Companies

Pipeline Gaps and Opportunities

Unmet Needs

1. Disease-modifying therapies for early intervention - Most advanced programs target moderate-to-severe AD; need for prodromal/preclinical trials

2. Combination approaches - Limited combination therapy signals in current pipeline

3. Biomarker-positive enrichment - Only 9.2% of AD trials include biomarker endpoints

4. Non-antibody modalities - Heavy reliance on monoclonal antibodies; need for small molecule and gene therapy approaches

Opportunity Areas

1. Anti-oligomer-specific antibodies - Targeting toxic soluble oligomers rather than plaques

2. Peripheral sink approaches - Reducing peripheral amyloid to drive brain clearance

3. Multi-target approaches - Combined Aβ/tau targeting

4. Genetic risk stratification - APOE4-enriched trials

Investment Themes

Consolidation Phase

The amyloid therapeutic space has consolidated following the FDA approvals of Leqembi and Donanemab. Investment is shifting toward:

1. Real-world evidence generation - Post-approval studies

2. Early intervention - Preclinical and prodromal AD

3. Biomarker development - Plasma and PET biomarkers for patient selection

Key Challenges

1. Safety monitoring - ARIA (amyloid-related imaging abnormalities) requires careful monitoring

2. Treatment duration - Long-term treatment effects unclear

3. Access and reimbursement - Pricing and coverage decisions pending

Cross-Links to Related Pages

• Alzheimer’s Disease

• Amyloid Cascade Pathway

• Amyloid-beta Protein

• Alzheimer’s Disease Investment Landscape

• Anti-Tau Therapeutics Investment Landscape

Clinical Trials

For current clinical trials targeting amyloid-beta and related pathways in Alzheimer’s disease, see:

• Clinical Trials: Alzheimer’s Disease

See Also

• Alzheimer’s Disease

• Amyloid Cascade Pathway

• Anti-Tau Therapeutics

• Tau Protein

• Beta-Secretase Inhibitors

External Links

• ClinicalTrials.gov - Alzheimer’s Disease

• FDA - Alzheimer’s Disease Drug Approvals

• Alzheimer’s Association